Journal article
A phase I study of vorinostat (VOR) in combination with capecitabine (CAP) in patients (pts) with advanced solid tumors
Abstract
3576
Background: VOR (suberoylanilide hydroxamic acid; SAHA) is a small molecule inhibitor of histone deacetylase (HDAC) that binds directly to the enzyme’s active site in the presence of a zinc ion. Aberrant HDAC activity has been implicated in a variety of cancers. The combination of 5-fluorouracil and VOR is synergistic in preclinical tumor models. Methods: This phase I study evaluated safety, tolerability, and the …
Authors
Tang P; Oza A; Townsley C; Siu L; Pond G; Sarveswaran P; Webster S; Zwiebel J; Chen E
Journal
Journal of Clinical Oncology, Vol. 25, No. 18_suppl, pp. 3576–3576
Publisher
American Society of Clinical Oncology (ASCO)
Publication Date
June 20, 2007
DOI
10.1200/jco.2007.25.18_suppl.3576
ISSN
0732-183X